Mosaic Immunoengineering Inc's Comment on Supply Chain
Contract manufacturers involved in the production of product candidates are subject to regulation by the U.S. Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (FDCA) and the Public Health Service (PHS) Act, as well as by comparable authorities in other countries. Their activities, including design, manufacturing, safety, efficacy, handling, labeling, storage, record-keeping, advertising, promotion, and marketing, must comply with these regulatory requirements. Biologic pharmaceuticals require sterile manufacturing processes due to their heat sensitivity and susceptibility to microbial contamination. The FDA approval process for biologics involves preclinical testing, submission of an Investigational New Drug (IND) application, Institutional Review Board (IRB) approval, clinical trials, submission of a Biologics License Application (BLA), review by an FDA Advisory Committee, FDA filing determination, pre-approval inspection of manufacturing facilities for current Good Manufacturing Practice (cGMP) compliance, and final FDA review and approval prior to commercial marketing or sale in the United States.
Mosaic Immunoengineering Inc's Comment on Supply Chain
Contract manufacturers involved in the production of product candidates are subject to regulation by the U.S. Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (FDCA) and the Public Health Service (PHS) Act, as well as by comparable authorities in other countries. Their activities, including design, manufacturing, safety, efficacy, handling, labeling, storage, record-keeping, advertising, promotion, and marketing, must comply with these regulatory requirements. Biologic pharmaceuticals require sterile manufacturing processes due to their heat sensitivity and susceptibility to microbial contamination. The FDA approval process for biologics involves preclinical testing, submission of an Investigational New Drug (IND) application, Institutional Review Board (IRB) approval, clinical trials, submission of a Biologics License Application (BLA), review by an FDA Advisory Committee, FDA filing determination, pre-approval inspection of manufacturing facilities for current Good Manufacturing Practice (cGMP) compliance, and final FDA review and approval prior to commercial marketing or sale in the United States.
Sources:
Mosaic Immunoengineering Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Mosaic Immunoengineering Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
